Safety, biodistribution, and exploratory clinical outcomes of a novel intra-articular IL-1Ra gene therapy (PCRX-201) in moderate-to-severe knee osteoarthritis: 2-year results of a phase 1 study

Annals of the Rheumatic Diseases · Published 2026-08-01 · DOI 10.1016/j.ard.2026.06.034

Free full text

Authors (10)

Stanley Cohen, Marc C. Hochberg, Alan Kivitz, Nino Joy, J. Derek Jackson, Mi-Jeong Kim, Lucia Sanchez-Gonzalez, Mary DiGiorgi, Jonathan Slonin, Philip G. Conaghan

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Cohen, S., Hochberg, M., Kivitz, A., et al. (2026). Safety, biodistribution, and exploratory clinical outcomes of a novel intra-articular IL-1Ra gene therapy (PCRX-201) in moderate-to-severe knee osteoarthritis: 2-year results of a phase 1 study. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.06.034

Related articles

• Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment · Annals of the Rheumatic Diseases · 2026 · Same journal
• Response to correspondence on ‘Final validation of the hierarchical framework for outcomes in axial spondyloarthritis: longitudinal determinants of health-related quality of life’ · Annals of the Rheumatic Diseases · 2026 · Same journal
• Mitochondrial-impaired ductal epithelium fuels TLS formation in Sjögren’s disease · Annals of the Rheumatic Diseases · 2026 · Same journal
• Development and validation of quality indicators for lupus nephritis, based on the 2025 EULAR recommendations: adherence trends and impact on clinical outcomes · Annals of the Rheumatic Diseases · 2026 · Same journal
• Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis · Annals of the Rheumatic Diseases · 2026 · Same journal
• Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countries · Annals of the Rheumatic Diseases · 2026 · Same journal
• Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma · Annals of the Rheumatic Diseases · 2026 · Same journal
• Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project · Annals of the Rheumatic Diseases · 2026 · Same journal
• Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series · Annals of the Rheumatic Diseases · 2026 · Same journal
• Symmetrical dimethylarginine as the central antigenic determinant of anti-Smith autoantibodies in systemic lupus erythematosus · Annals of the Rheumatic Diseases · 2026 · Same journal